- Home
- AS vs NBIX Comparison
AS vs NBIX Comparison
Compare AS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AS
- NBIX
- Stock Information
- Founded
- AS 1950
- NBIX 1992
- Country
- AS Finland
- NBIX United States
- Employees
- AS N/A
- NBIX N/A
- Industry
- AS
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AS
- NBIX Health Care
- Exchange
- AS NYSE
- NBIX Nasdaq
- Market Cap
- AS 14.3B
- NBIX 12.4B
- IPO Year
- AS 2024
- NBIX 1996
- Fundamental
- Price
- AS $38.14
- NBIX $134.33
- Analyst Decision
- AS Strong Buy
- NBIX Strong Buy
- Analyst Count
- AS 10
- NBIX 21
- Target Price
- AS $39.00
- NBIX $165.14
- AVG Volume (30 Days)
- AS 3.8M
- NBIX 821.3K
- Earning Date
- AS 08-19-2025
- NBIX 07-30-2025
- Dividend Yield
- AS N/A
- NBIX N/A
- EPS Growth
- AS N/A
- NBIX N/A
- EPS
- AS 0.38
- NBIX 2.96
- Revenue
- AS $5,463,300,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- AS $20.62
- NBIX $16.29
- Revenue Next Year
- AS $13.45
- NBIX $15.08
- P/E Ratio
- AS $100.33
- NBIX $45.11
- Revenue Growth
- AS 20.27
- NBIX 21.73
- 52 Week Low
- AS $10.11
- NBIX $84.23
- 52 Week High
- AS $40.21
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- AS 56.87
- NBIX 70.92
- Support Level
- AS $37.51
- NBIX $127.03
- Resistance Level
- AS $39.04
- NBIX $135.94
- Average True Range (ATR)
- AS 1.18
- NBIX 2.85
- MACD
- AS -0.22
- NBIX 0.47
- Stochastic Oscillator
- AS 51.10
- NBIX 87.52
About AS AMER SPORTS INC
Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $4.4 billion in 2023. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2023, the firm generates 40% of its revenue from the Americas, 33% from Europe, the Middle East, and Africa, 19% from China, and 7% from Asia-Pacific, excluding China.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.